HIV-specific T-cell induction
US6656471B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 16, 1999 |
| Grant date | Dec 2, 2003 |
| Priority date | — |
| Expiry date | Nov 16, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/826
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention discloses diagnostic, preventative, and treatment therapies of AIDS involving determining whether a subject exhibits an HLA-Cw7-restricted CTL response. Some methods are directed to the use of HLA-Cw7 as a genetic marker for long-term non-progression and amenability to treatment therapies. Diagnostic methods include a method for predicting long term non-progression in an HIV-infected subject. Preventative and treatment methods encompass determining whether a subject exhibits or can exhibit an HLA-Cw7-restricted CTL response. They also encompass ways of eliciting such a response, if necessary. Furthermore, some of the methods involve administering one or more HIV polypeptides or peptides, or polynucleotides encoding them, as a treatment therapy to prevent the development of AIDS.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.